- Internship - Washington University St. Louis - Barnes Jewish Hospital (2004-2005), Internal Medicine
- Medical School - Christian Medical College, India (1994-2000)
- Graduate School - University of California, Irvine (2000-2004), Physiology & Biophysics
- Residency - Washington University/Barnes Jewish Hospital (2005-2008)
- Fellowship - University of Michigan Medical School (2008-2010), Movement Disorders
Vikram Shakkottai, M.D., Ph.D.
Vice Chair for Basic Research, Section Head, Movement Disorders
- Dedman Family Distinguished Chair in Neurological Disease
- Neurology
- Cerebellar Ataxia, Inherited and Sporadic Disorders of Cerebellar Dysfunction
- Balance Disorders
Biography
Vikram Shakkottai, M.D., Ph.D., obtained his medical degree at the Christian Medical College, Vellore, India, and his Ph.D. at the University of California, Irvine. He received his neurology residency training at Washington University/Barnes-Jewish hospital, and was a fellow in movement disorders at the University of Michigan. He joined the full-time faculty at University of Michigan in 2010. He moved to UTSW in 2021.
The long-term goal of Dr. Shakkottai’s clinical and laboratory research is to determine whether alterations in neuronal physiology contribute to motor dysfunction and to translate preclinical murine model research to human clinical trials for cerebellar ataxia. Work in Dr. Shakkottai’s laboratory has identified shared dysfunction in the cerebellum in murine models of ataxia, with identification of several ion channels that act in concert, and converging on large-conductance calcium-activated potassium (BK) channels. BK channels are likely a key target for therapy in degenerative ataxias.
Dr. Shakkottai's clinical interests include cerebellar ataxia; inherited and sporadic disorders of cerebellar dysfunction; balance disorders; and other movement disorders.
Education & Training
Books & Publications
-
Publications
-
Discovery of novel activators of large-conductance calcium-activated potassium channels for the treatment of cerebellar ataxia.
Srinivasan SR, Huang H, Chang WC, Nasburg JA, Nguyen HM, Strassmaier T, Wulff H, Shakkottai VG, Molecular pharmacology 2022 Apr -
A Chlorzoxazone-Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1.
Bushart DD, Huang H, Man LJ, Morrison LM, Shakkottai VG, Movement disorders : official journal of the Movement Disorder Society 2020 Nov -
Altered Capicua expression drives regional Purkinje neuron vulnerability through ion channel gene dysregulation in spinocerebellar ataxia type 1.
Chopra R, Bushart DD, Cooper JP, Yellajoshyula D, Morrison LM, Huang H, Handler HP, Man LJ, Dansithong W, Scoles DR, Pulst SM, Orr HT, Shakkottai VG, Human molecular genetics 2020 Nov 29 19 3249-3265 -
Multiple system atrophy pathology is associated with primary Sjogren's syndrome.
Conway KS, Camelo-Piragua S, Fisher-Hubbard A, Perry WR, Shakkottai VG, Venneti S, JCI insight 2020 08 5 15 -
Nicotinamide Pathway-Dependent Sirt1 Activation Restores Calcium Homeostasis to Achieve Neuroprotection in Spinocerebellar Ataxia Type 7.
Stoyas CA, Bushart DD, Switonski PM, Ward JM, Alaghatta A, Tang MB, Niu C, Wadhwa M, Huang H, Savchenko A, Gariani K, Xie F, Delaney JR, Gaasterland T, Auwerx J, Shakkottai VG, La Spada AR, Neuron 2020 02 105 4 630-644.e9 -
Protein kinase C activity is a protective modifier of Purkinje neuron degeneration in cerebellar ataxia.
Chopra R, Wasserman AH, Pulst SM, De Zeeuw CI, Shakkottai VG, Human molecular genetics 2018 04 27 8 1396-1410 -
Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2.
Dell'Orco JM, Pulst SM, Shakkottai VG, Human molecular genetics 2017 10 26 20 3935-3945 -
Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability.
Dell'Orco JM, Wasserman AH, Chopra R, Ingram MA, Hu YS, Singh V, Wulff H, Opal P, Orr HT, Shakkottai VG, The Journal of neuroscience : the official journal of the Society for Neuroscience 2015 Aug 35 32 11292-307 -
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3.
Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL, The Journal of neuroscience : the official journal of the Society for Neuroscience 2011 Sep 31 36 13002-14 -
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia.
Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG, The Journal of clinical investigation 2004 Feb 113 4 582-90
-
Discovery of novel activators of large-conductance calcium-activated potassium channels for the treatment of cerebellar ataxia.
Clinical Focus
- Cerebellar Ataxia, Inherited and Sporadic Disorders of Cerebellar Dysfunction
- Balance Disorders
- Movement Disorders
Results: 1 Locations
Neurology Clinic - Movement Disorders
at James W. Aston Ambulatory Care Center 5303 Harry Hines Blvd., 8th FloorDallas, Texas 75390 214-645-8800 Directions to Neurology Clinic - Movement Disorders Parking Info for Neurology Clinic - Movement Disorders